TMCnet News
OTCPicks.com: OTCPicks.com Daily Market Movers Digest Midday Report for Tuesday, March 3rd BLUG, ADDE, SHMN, BRKR(M2 PressWIRE Via Acquire Media NewsEdge) RDATE:03032009 Our Stocks to Watch today include Blugrass Energy Inc. (OTCBB: BLUG), Adoodle Inc. (OTC: ADDE), SOHM Inc. (OTC: SHMN) and Bruker Corp. (Nasdaq: BRKR). Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover's Digest Newsletter and Email Stock Watch Alerts. BLUGRASS ENERGY INCORPORATED (OTCBB: BLUG) Detailed Quote: http://www.otcpicks.com/quotes/BLUG.php Company Profile: http://www.otcpicks.com/blugrass-energy.htm Blugrass Energy, Inc. is an oil and gas development and exploration company based in the United States that is traded on the Over the Counter Bulletin Board under the Symbol BLUG. The goal of BLUG is to grow through internally generated and developed prospects, participation with industry partners in oil and gas exploration and in targeted joint ventures. BLUG News: March 3 - Blugrass Provides Update on Acquisitions and Joint Ventures Blugrass Energy Inc. (OTCBB: BLUG) provided the following updates on its acquisitions and Western Kentucky Joint Venture: On Blugrass's previously announced acquisition of acreage in Eastern Kentucky, Blugrass now believes that the reserves could potentially be more than originally thought after further review. Also, Blugrass has been successful in restructuring the terms of the transaction whereby the company will not be issuing any shares as part of the consideration in the transaction. Based on the closing price of Blugrass stock on Monday, March 2nd this is a savings of over $240,000 in the transaction for Blugrass. Blugrass has commenced work on evaluating and prioritizing drilling locations on this acreage. Based on the mutual agreement by the Parties, the closing date of the transaction is now expected to occur on or before Mid April 2009. The Joint Venture that Blugrass announced to develop 5000 acres in the New Albany Shale on February 4, 2009, has been actively moving forward. Just this week, another company announced their 10th commercially successful well in a row in an area that is analogous to the acreage of the Joint Venture. The Joint Venture participants have designated the targeted Area of Mutual Interest as, "Bullseye". Currently the steps being taken in the Joint Venture include commencing the evaluation of potential drilling locations, commencing work on the development schedule to facilitate the permitting process, finalizing the initial negotiations on a long term gas purchase agreement, and holding discussions with an industry partner to oversee the drilling and completion work on the wells. Blugrass is currently holding discussions with another company about the possibility of entering into a Joint Venture in Eastern Kentucky that would allow Blugrass to participate in an acreage block within the Big Sinking Oil Field. The Big Sinking Oil Field is the Largest Oil Field in the Eastern United States and is classified as a "giant" oil field by the United States Geological Society. Blugrass hopes that a transaction will be finalized in the near future, but as of today an agreement or Letter of Intent has not been reached between the Parties. ADOODLE INCORPORATED (OTC: ADDE) Detailed Quote: http://www.otcpicks.com/quotes/ADDE.php Company Profile: http://www.otcpicks.com/adoodle-inc./adoodle-inc.htm The NOXO Division of Adoodle focuses on Olfaction Perception Altering - Stimulation and Inhibition. Adoodle presently has several NOXO Olfactory Perception Inhibition products. One is a petrolatum based gel version of NOXO, and the other is a Soy based NOXO cream that is easily absorbed into the skin. NOXO effectively inhibits offensive odor perception within the brain rather than just trying to artificially mask odors. The gel or cream is applied under the nostrils from a small one-time use packet and has a myriad of different vertical market applications. If you work in an environment where you are enduring noxious odors, you should try NOXO. ADDE News: March 2 - Adoodle, Inc. Releases New, All Natural, Odor-Blocking NOXO Formulation Adoodle, Inc. (OTC: ADDE) announced a new and improved, all natural formulation for NOXO which is immediately available for both wholesale and retail purchase. NOXO is a skin cream , applied topically under the nostrils, consisting of 14 natural ingredients including important essential oils , specifically formulated to block nauseating, offensive and unpleasant odors. NOXO does not work by masking odors, but rather is based on advanced olfactory perception altering technology. The new NOXO product formulation uses an FDA cosmetically-approved base containing a special soy formulated skin cream. When applied above the upper lip, it is absorbed by the skin and effectively masks extremely offensive odors such as decaying and burnt flesh, operating room odors, anaerobic bacteria volatiles, urine and feces, gastric bleed vomit and more. It is also longer lasting and more efficient than the petroleum-based NOXO product formulation recently marketed by the company . Noxious odors can cause stress to first responders, health care professionals (dental and medical) and others that work in areas where extremely offensive odors are a detriment to their own productivity and health. Uniquely formulated NOXO is based on advanced olfactory perception altering technology developed by Dr. V Ruth Pinney who is a director of Adoodle and who also directs the research at the company's new research center in The Woodlands, Texas. Dr. Pinney worked with the Department of Justice to commercialize this product in order to support the brave efforts of our military, first responders, and law enforcement personnel. The earlier, first-generation product has been used extensively around the world including NYFD and first responders after 9/11, Dover AFB, and after natural disasters resulting from tsunamis, earthquakes, and hurricanes. This technology and the new second generation product has now found it's way into the medical and dental arena . The new all natural NOXO has no market competition and is anticipated to have far-reaching applications around the world for the military, first-responders, emergency workers, disaster relief workers, hospitals, mortuaries, nursing homes, medical personnel and fire fighters, as well as numerous other industrial and consumer uses where people must endure noxious smells. Dr. V Ruth Pinney, Adoodle, Inc's director and head of new product development, says, "This is a great day for Adoodle and NOXO. By introducing this new version of NOXO we have knocked aside any remaining barriers for NOXO's use in various vertical market segments and applications. This new NOXO formulation is absorbed into the skin and is not visible after its application like our older petrolatum based NOXO product. This is an important product evolution which will facilitate Noxo's use by nurses, surgeons, periodontists, dialysis units, burn care units and other market sectors . Also, this new formulation - since it is absorbed into the skin - cannot be inadvertently wiped off which is great for product applications in various vertical market sectors." SOHM INCORPORATED (OTC: SHMN) "Up 66.67% in morning trading" Detailed Quote: http://www.otcpicks.com/quotes/SHMN.php SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters is located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia. SHMN News: March 3 - SOHM Expanding Generic Drug Distribution Within Emerging Pharmaceutical Market in Southeast Asia: Indonesia, Thailand, the Philippines, and Malaysia SOHM, Inc. (OTC: SHMN), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories, today announced that the Company is expanding its generic drug distribution within the emerging pharmaceutical market in Southeast Asia; specifically in Indonesia, Thailand, the Philippines, and Malaysia. The Company's direct manufacturing of generic pharmaceuticals allows pricing advantages and distribution of quality drugs to consumers remaining underserved or with limited access to medicine in this region. SOHM is positioned to capitalize on the health issues not being addressed such as different contagious diseases and life style disorders such as cardiovascular, diabetes, musculoskeletal disorders and cancer to expand the market and serve the populations of these countries. Southeast Asia is the fourth-largest pharmaceutical market in the world, behind the United States, Japan, and Europe. Southeast Asia is also the world's fastest-growing pharmaceutical market. Factors driving this market expansion include economic growth, a broadening middle class, growing and aging population, increasing economic liberalization, and an expanded government and private-sector role in improving health care. Vice President for Corporate Strategy at SOHM, Inc. Shailesh Shah stated, "Pharmaceutical markets in Southeast Asia, Indonesia, the Philippines, Thailand, and Malaysia are all growing rapidly as people demand access to modern drugs and as these emerging economies expand. Despite the challenges in the current economic climate much of the populations of these countries have a great need for basic pharmaceuticals that are either too expensive or not available to vast populations in this region. SOHM fills this need and we are very excited to provide a valuable service to these countries and their citizens." BRUKER CORPORATION (NASDAQ: BRKR) "Up 26.54% in morning trading" Detailed Quote: http://www.otcpicks.com/quotes/BRKR.php Bruker Corporation engages in the design, manufacture, service, and marketing of analytical and life science systems and associated products worldwide. Its Bruker AXS segment offers x-ray systems, computer-controlled positioning systems, sample handling devices, and data collection and analysis software to acquire, analyze, and manage elemental and molecular information. This segment also provides system up-gradation, training, and support services; consumables; replacement parts; and accessory items, including sample handling devices, temperature and pressure control devices, x-ray optics, and software packages. The company's Bruker Daltonics segment offers mass spectrometers that measure the mass or weight of molecules that can provide information on the identity, quantity, and primary structure of molecules. This segment also provides portable analytical and bioanalytical detection systems and related products for CBRN detection; consumables for preparing, purifying, and processing samples prior to mass spectrometric analyses, as well as for collecting samples for CBRN detection; data acquisition and analysis software, and bioinformatics software; and system up gradation, training, and support services. Its Bruker Optics segment manufactures and distributes research, analytical, and process analysis instruments for life science, pharmaceutical analysis, food and agricultural analysis in research and development, quality control, and process analysis applications. This segment also offers replacement parts, consumables, and accessory items, as well as system up-gradation, training, and support services. It serves life science research, pharmaceutical, biotechnology, materials and chemical analysis, and molecular diagnostics research industries. The company was founded in 1991. It was formerly known as Bruker BioSciences Corporation and changed its name to Bruker Corporation in February 2008. The company is headquartered in Billerica, Massachusetts. BRKR News: March 3 - Bruker Corporation Reports Financial Results for the Fourth Quarter and Full Year 2008 Bruker Corporation (Nasdaq: BRKR) reported financial results for the fourth quarter and year ended December 31, 2008. Financial Results In the fourth quarter of 2008, revenue was $315.2 million, compared to revenue of $344.8 in the fourth quarter of 2007. Excluding the effects of foreign currency translation, fourth quarter revenue decreased by 3% year-over-year. Sequentially, revenues in the fourth quarter of 2008 increased by 30%, compared to revenue of $242.1 million in the third quarter of 2008. For the year 2008, revenue increased by 7% to $1,107.1 million, compared to revenue of $1,032.4 million for the year 2007. Excluding the effects of foreign currency translation, full year 2008 revenue increased by 3% year-over-year. GAAP operating income in the fourth quarter of 2008 was $48.9 million, compared to $66.4 million in the fourth quarter of 2007. For the year 2008, GAAP operating income was $108.2 million, compared to $137.7 million for the year 2007. Including the adjustments in the attached reconciliation, non-GAAP operating income in the fourth quarter of 2008 was $52.6 million, compared to $74.0 million in the fourth quarter of 2007. For the year 2008, non-GAAP operating income was $121.2 million, compared to $147.3 million in 2007. GAAP net income for the fourth quarter of 2008 was $26.2 million, or $0.16 per diluted share, compared to $40.3 million, or $0.24 per diluted share, in the fourth quarter of 2007. For the year 2008, GAAP net income was $64.9 million, or $0.39 per diluted share, compared to $98.9 million, or $0.60 per diluted share, in the year 2007. Including the adjustments in the attached reconciliation, non-GAAP net income for the fourth quarter of 2008 was $30.4 million, or $0.18 per diluted share, compared to $47.7 million, or $0.29 per diluted share, in the fourth quarter of 2007. For the year 2008, non-GAAP net income was $77.9 million, or $0.47 per diluted share, compared to $107.9 million, or $0.66 per diluted share, in 2007. Cash flow from operations for the full year 2008 was $105.5 million, compared to $120.9 million in 2007. Free cash flow, defined as operating cash flow less capital expenditures, was $58.1 million during 2008, compared to $93.9 million during 2007. Capital expenditures for the year 2008 were $47.4 million, which was approximately $20 million higher than in 2007 due to the expansion of two manufacturing locations in 2008. During the year 2008, the Company repaid $187.0 million of the debt incurred to finance the Bruker BioSpin Group acquisition in February 2008. As of December 31, 2008, Bruker had cash and cash equivalents of $167.7 million, and net debt of $56.1 million. Comment and Outlook Frank Laukien, President and CEO, commented: "Our fourth quarter was again our strongest quarter of the year. In the fourth quarter of 2008, we had strong new order bookings and we ended the year 2008 with a healthy backlog. However, in 2008 our margins were well below our goals, and we have put aggressive cost-cutting initiatives in place, which include voluntary top-management salary decreases for 2009, selected staff reductions, hiring and salary freezes for 2009, and cut-backs in discretionary spending. In addition, we continue to drive numerous gross margin improvement projects, from which we expect to benefit in 2009 and beyond." Dr. Laukien continued with an outlook for the year 2009: "This year offers significant challenges due to the deepening global recession and uncertain outlook. Bruker is relatively well positioned to deal with these challenges, as we have an exceptionally strong technology, IP and product portfolio and broad international diversification. Bruker also derives more than 60% of its revenue from universities, medical schools, as well as other non-profit and government customers, who tend to be less sensitive to economic conditions. Some of our demand drivers are even counter-cyclical, and a few of our customers have already begun to benefit from counter-cyclical supplementary budgets and various national stimulus packages." Bruker's CFO Bill Knight added: "Financially, we expect to continue to have a strong balance sheet, positive operating and free cash flow, ample borrowing capacity, and clear opportunities to improve our margins, balance sheet metrics and cash flow generation. On this solid financial foundation, we will invest further in our future, even during 2009, with additional market development in attractive applied markets, including food and consumer safety, pharma PAT, forensics and toxicology, as well as in clinical research and IVD, homeland security and explosives detection, and advanced superconducting magnets and devices. Leveraging our strong technology base into these near-term additional growth and margin opportunities makes strategic sense for Bruker, and we intend to emerge from this recession as an even stronger company." Mr. Knight continued: "Given the apparent further deterioration of the global economy in January and February 2009, and the uncertainty of the timing and effect of various international stimulus efforts, forecasting for the full year 2009 is extremely difficult. We have nevertheless established internal financial goals for ourselves in 2009, and intend to drive Bruker towards a currency-adjusted low single digit percentage decline in revenue or flat revenue, an improvement in non-GAAP operating margin and EPS, and a positive net cash position before the end of 2009." ABOUT OTCPICKS.COM OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover's Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at [email protected]. Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever. Release of Liability: Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has been compensated one thousand five hundred dollars by a third party (BlueWave Advisors) for BLUG advertising and promotional services. OTCPick.com has been compensated one hundred seventy thousand free trading shares by a non-controlling third party (OTC Investor Source) for ABVI advertising and promotional services. OTCPicks.com has been compensated sixty four thousand free trading shares from a non-controlling third party for ADDE advertising and promotional services. For a complete list of disclosures go to http://www.otcpicks.com/disclosure-details.htm. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled. The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results. Third Party Web Sites and Information: OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only. CONTACT: Brian Dean, Publisher, OTCPicks.com Tel: +1 972 546 3740 e-mail: [email protected] ((M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [email protected])). Copyright ? 2009 M2 Communications Ltd. |